Impaired detection of omicron by SARS-CoV-2 rapid antigen tests
Top Cited Papers
Open Access
- 20 February 2022
- journal article
- research article
- Published by Springer Nature in Medical Microbiology and Immunology
- Vol. 211 (2-3) , 105-117
Abstract
Since autumn 2020, rapid antigen tests (RATs) have been implemented in several countries as an important pillar of the national testing strategy to rapidly screen for infections on site during the SARS-CoV-2 pandemic. The current surge in infection rates around the globe is driven by the variant of concern (VoC) omicron (B.1.1.529). Here, we evaluated the performance of nine SARS-CoV-2 RATs in a single-centre laboratory study. We examined a total of 115 SARS-CoV-2 PCR-negative and 166 SARS-CoV-2 PCR-positive respiratory swab samples (101 omicron, 65 delta (B.1.617.2)) collected from October 2021 until January 2022 as well as cell culture-expanded clinical isolates of both VoCs. In an assessment of the analytical sensitivity in clinical specimen, the 50% limit of detection (LoD50) ranged from 1.77 × 106 to 7.03 × 107 RNA copies subjected to the RAT for omicron compared to 1.32 × 105 to 2.05 × 106 for delta. To score positive in these point-of-care tests, up to 10-fold (LoD50) or 101-fold (LoD95) higher virus loads were required for omicron- compared to delta-containing samples. The rates of true positive test results for omicron samples in the highest virus load category (Ct values < 25) ranged between 31.4 and 77.8%, while they dropped to 0–8.3% for samples with intermediate Ct values (25–30). Of note, testing of expanded virus stocks suggested a comparable RAT sensitivity of both VoCs, questioning the predictive value of this type of in vitro-studies for clinical performance. Given their importance for national test strategies in the current omicron wave, awareness must be increased for the reduced detection rate of omicron infections by RATs and a short list of suitable RATs that fulfill the minimal requirements of performance should be rapidly disclosed.Keywords
Funding Information
- Free State of Bavaria (BayVOC, FOR-COVID)
- Universitätsmedizin Greifswald
This publication has 51 references indexed in Scilit:
- Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread?Journal of Clinical Virology, 2021
- Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital settingMedical Microbiology and Immunology, 2021
- Limits and Opportunities of SARS-CoV-2 Antigen Rapid Tests: An Experienced-Based PerspectivePathogens, 2021
- Prospective Longitudinal Serosurvey of Healthcare Workers in the First Wave of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic in a Quaternary Care Hospital in Munich, GermanyClinical Infectious Diseases, 2021
- Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2Science Translational Medicine, 2020
- SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomographyNature Communications, 2020
- Differential Expression of Viral Transcripts From Single-Cell RNA Sequencing of Moderate and Severe COVID-19 Patients and Its Implications for Case SeverityFrontiers in Microbiology, 2020
- Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020Eurosurveillance, 2020
- A super-spreader of COVID-19 in Ningbo city in ChinaJournal of Infection and Public Health, 2020
- Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure developmentProceedings of the National Academy of Sciences, 2020